What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Louis Fehrenbacher mostly deals with Internal medicine, Oncology, Surgery, Breast cancer and Bevacizumab.
His Internal medicine study frequently draws connections to adjacent fields such as Gastroenterology.
His Gastroenterology research incorporates themes from Irinotecan and Clinical endpoint.
His study in Oncology is interdisciplinary in nature, drawing from both Cancer and Atezolizumab.
He works mostly in the field of Breast cancer, limiting it down to topics relating to Gynecology and, in certain cases, Hormonal therapy, Hormone therapy, Discontinuation, Breast disease and Lapatinib.
His Bevacizumab study integrates concerns from other disciplines, such as Combined Modality Therapy, Clinical trial and Randomized controlled trial.
His most cited work include:
- BEVACIZUMAB PLUS IRINOTECAN, FLUOROURACIL, AND LEUCOVORIN FOR METASTATIC COLORECTAL CANCER (9191 citations)
- Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer (4382 citations)
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer (2697 citations)
What are the main themes of his work throughout his whole career to date?
Louis Fehrenbacher mainly investigates Internal medicine, Oncology, Breast cancer, Surgery and Chemotherapy.
His Oncology research incorporates themes from Phases of clinical research, Regimen, Atezolizumab, Hazard ratio and Gemcitabine.
His research in Breast cancer intersects with topics in Gynecology, Cyclophosphamide, Adjuvant therapy and Clinical trial.
His Surgery research integrates issues from Gastroenterology, Placebo, Colorectal cancer and Adverse effect.
His Chemotherapy research is multidisciplinary, relying on both Adjuvant, Metastatic breast cancer and non-small cell lung cancer.
Louis Fehrenbacher has included themes like Irinotecan and Capecitabine in his Bevacizumab study.
He most often published in these fields:
- Internal medicine (87.37%)
- Oncology (64.74%)
- Breast cancer (44.21%)
What were the highlights of his more recent work (between 2015-2020)?
- Internal medicine (87.37%)
- Oncology (64.74%)
- Breast cancer (44.21%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Oncology, Breast cancer, Atezolizumab and Docetaxel.
His Internal medicine study combines topics in areas such as Placebo and Surgery.
His research integrates issues of Neuroendocrine tumors and Oxaliplatin, FOLFOX in his study of Surgery.
The various areas that he examines in his Oncology study include Gemcitabine, Chemotherapy, Clinical endpoint and Hazard ratio.
His Breast cancer research includes elements of Clinical trial and Cyclophosphamide.
His Atezolizumab research is multidisciplinary, incorporating elements of Biomarker, Lung cancer, Adverse effect and Cancer immunotherapy.
Between 2015 and 2020, his most popular works were:
- Atezolizumab Versus Docetaxel for Patients With Previously Treated Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, Open-Label, Phase 2 Randomised Controlled Trial (1436 citations)
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. (529 citations)
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. (391 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Internal medicine, Oncology, Breast cancer, Atezolizumab and Docetaxel are his primary areas of study.
His study in Clinical endpoint, Cancer, Randomized controlled trial and Trastuzumab is done as part of Internal medicine.
His work deals with themes such as Bevacizumab, Surgery, Capecitabine and Hazard ratio, which intersect with Oncology.
His Bevacizumab study results in a more complete grasp of Chemotherapy.
His work on Survival rate as part of general Surgery research is frequently linked to PD-L1 inhibitor, bridging the gap between disciplines.
The study of Breast cancer is intertwined with the study of Gynecology in a number of ways.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
